News

The University of Queensland’s technology transfer company, UniQuest, will partner with the biotechnology company CSL Limited to develop and commercialize the university’s antigen specific immune tolerance induction (ASITI) technology for the treatment of Sjogren’s syndrome. As an autoimmune disorder, Sjogren’s syndrome involves the immune system…

A new study has uncovered two potential biomarkers of primary Sjögren’s syndrome (pSS): progranulin (PGRN) and Oxford 40 ligand (OX40L). People with pSS have higher levels of these two proteins compared to healthy volunteers. The study, “Clinical Significance of Progranulin Correlated With Serum Soluble Oxford 40 Ligand in Primary Sjögren’s…